Arthur W Lee

US Patent:

7407978, Aug 5, 2008

Filed:

Oct 8, 2002

Appl. No.:

10/265902

Inventors:

Partha Neogi - Fremont CA, US
Debendranath Dey - Fremont CA, US
Bishwajit Nag - Union City CA, US
Arthur Lee - San Francisco CA, US

Assignee:

Theracos, Inc. - Sunnyvale CA

International Classification:

A61K 31/425

US Classification:

514369

Abstract:

Novel diphenylethylene compounds and derivatives thereof containing thiazolidinedione or oxazolidinedione moieties are provided which are effective in lowering blood glucose level, serum insulin, triglyceride and free fatty acid levels in animal models of Type II diabetes. The compounds are disclosed as useful for a variety of treatments including the treatment of inflammation, inflammatory and immunological diseases, insulin resistance, hyperlipidemia, coronary artery disease, cancer and multiple sclerosis.

US Patent:

7718682, May 18, 2010

Filed:

Apr 2, 2008

Appl. No.:

12/078662

Inventors:

Partha Neogi - Fremont CA, US
Debendranath Dey - Fremont CA, US
Satyanarayana Medicherla - Cupertino CA, US
Arthur Lee - San Francisco CA, US

Assignee:

Theracos, Inc. - Sunnyvale CA

International Classification:

A61K 31/426

US Classification:

514369

Abstract:

Novel diphenylethylene compounds and derivatives thereof containing thiazolidinedione or oxazolidinedione moieties are provided which are effective in lowering blood glucose level, serum insulin, triglyceride and free fatty acid levels in animal models of Type II diabetes. The compounds are disclosed as useful for a variety of treatments including the treatment of inflammation, inflammatory and immunological diseases, insulin resistance, hyperlipidemia, coronary artery disease, cancer and multiple sclerosis.

US Patent:

20060235062, Oct 19, 2006

Filed:

Oct 8, 2003

Appl. No.:

10/530757

Inventors:

Partha Neogi - FREMONT CA, US
Satyanarayana Medicherla - Cupertino CA, US
Bishwajit Nag - Union City CA, US
Arthur Lee - Cambridge MA, US

Assignee:

THERACOS, INC. - SUNNYVALE CA

International Classification:

A61K 31/426
A61K 31/421
A61K 31/4166

US Classification:

514369000, 514376000, 514389000, 548186000, 548227000, 548317100

Abstract:

Novel diphenylethylene compounds and derivatives thereof containing thiazolidinedione or oxazolidinedione moieties are provided which are effective in lowering blood glucose level, serum insulin, triglyceride and free fatty acid levels in animal models of Type II diabetes. The compounds are disclosed as useful for a variety of treatments including the treatment of inflammation, inflammatory and immunological diseases, insulin resistance, hyperlipidemia, coronary artery disease, cancer and multiple sclerosis.

US Patent:

20220347311, Nov 3, 2022

Filed:

Jun 30, 2022

Appl. No.:

17/854239

Inventors:

- Redwood City CA, US
- Stanford CA, US
David Y. Jackson - Redwood City CA, US
Arthur Lee - Redwood City CA, US
Edgar George Engleman - Atherton CA, US

Assignee:

Bolt Biotherapeutics, Inc. - Redwood City CA
The Board of Trustees of The Leland Stanford Junior University - Stanford CA

International Classification:

A61K 47/68
A61K 39/395
A61P 35/00

Abstract:

The invention provides an immunoconjugate of formula:or pharmaceutically acceptable salt thereof, wherein subscript r is an integer from 1 to 10, subscript n is an integer from about 2 to about 25, and “Ab” is an antibody construct that has an antigen binding domain that binds HER2. The invention further provides compositions comprising and methods of treating cancer with the immunoconjugate.

US Patent:

20220347312, Nov 3, 2022

Filed:

Sep 4, 2020

Appl. No.:

17/639620

Inventors:

- Redwood City CA, US
David Dornan - Redwood City CA, US
Romas Kudirka - Redwood City CA, US
Richard P. Laura - Redwood City CA, US
Arthur Lee - Redwood City CA, US
Brian Safina - Redwood City CA, US
Matthew Zhou - Redwood City CA, US

Assignee:

Bolt Biotherapeutics, Inc. - Redwood City CA

International Classification:

A61K 47/68

Abstract:

The invention provides a method for producing an immunoconjugate, the method comprising combining one or more compounds of Formula I and an antibody construct of Formula II to provide the immunoconjugate of Formula III, wherein TA is a therapeutic agent, L is a linker, r is an integer from 1 to 50, Ar is an aromatic moiety comprising a substituent selected from PEG, —SOCX, —NR, —NO, —SOR, —SOR, —CN, —CX, —POR, —OPOR, and salts thereof, each R independently is H, CX, or C-Calkyl, each X independently is hydrogen or a halogen, Y is CH, PEG, or a bond, n is an integer from 1 to 4, and PEG has the formula: —(CHCHO)m-(CH)—, where p is an integer from 1 to 5 and m is an integer from 2 to 50. The invention also provides an immunoconjugate and a composition of immunoconjugates formed from said method.

US Patent:

20220315537, Oct 6, 2022

Filed:

Jun 12, 2020

Appl. No.:

17/618729

Inventors:

- Redwood City CA, US
Michael N. Alonso - Redwood City CA, US
Romas Kudirka - Redwood City CA, US
Arthur Lee - Redwood City CA, US
Brian Safina - Redwood City CA, US
Matthew Zhou - Redwood City CA, US

Assignee:

Bolt Biotherapeutics, Inc. - Redwood City CA

International Classification:

C07D 223/16
C07H 15/203
C07D 403/10
C07D 403/12

Abstract:

The application provides macromolecule-supported compounds of Formula I or III comprising a macromolecular support linked by conjugation to one or more aminobenzazepine derivatives. The application also provides aminobenzazepine derivative intermediate compositions of Formula II comprising a reactive functional group. Such intermediate compositions are suitable substrates for formation of the macromolecule-supported compounds through a linker or linking moiety. The application further provides compositions comprising the macromolecule-supported compounds, as well as methods of treating cancer with the macromolecule-supported compounds.

US Patent:

20220226491, Jul 21, 2022

Filed:

Mar 13, 2020

Appl. No.:

17/437617

Inventors:

- Redwood City CA, US
- Stanford CA, US
David Dornan - Redwood City CA, US
Justin Kenkel - Redwood City CA, US
Romas Kudirka - Redwood City CA, US
Arthur Lee - Redwood City CA, US
Brian Safina - Redwood City CA, US
Matthew Zhou - Redwood City CA, US
Edgar George Engleman - Atherton CA, US

Assignee:

Bolt Biotherapeutics, Inc. - Redwood City CA
The Board of Trustees of The Leland Stanford Junior University - Stanford CA

International Classification:

A61K 47/68
A61K 31/437
A61K 47/54
A61P 35/00

Abstract:

The invention provides an immunoconjugate of formula (I) or (II). Antibody-adjuvant immunoconjugates of the invention, comprising an antibody construct that has an antigen binding domain that binds programmed death-ligand 1 (PD-L1) linked to one or more adjuvants, demonstrate superior pharmacological properties over conventional antibody conjugates. The invention further provides compositions comprising and methods of treating cancer with the immunoconjugate.

US Patent:

20220226492, Jul 21, 2022

Filed:

Mar 13, 2020

Appl. No.:

17/438203

Inventors:

- Redwood City CA, US
- Stanford CA, US
David Dornan - Redwood City CA, US
Romas Kudirka - Redwood City CA, US
Arthur Lee - Redwood City CA, US
Brian Safina - Redwood City CA, US
Matthew Zhou - Redwood City CA, US
Edgar George Engleman - Atherton CA, US

Assignee:

Bolt Biotherapeutics, Inc. - Redwood City CA
The Board of Trustees of The Leland Stanford Junior University - Stanford CA

International Classification:

A61K 47/68
A61K 47/54
A61P 35/00

Abstract:

The invention provides an immunoconjugate of formula (I) or (II). Antibody-adjuvant immunoconjugates of the invention, comprising an antibody construct that has an antigen binding domain that binds human epidermal growth factor receptor 2 (“HER2”) linked to one or more adjuvants, demonstrate superior pharmacological properties over conventional antibody conjugates. The invention further provides compositions comprising and methods of treating cancer with the immunoconjugate.